Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques LeLorier

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
JAAD International|August 19, 2021
Sex differences in factors associated with switch between systemic agents among individuals with psoriasis: A retrospective cohort study in Quebec, CanadaRaymond Milan, Jacques LeLorier, Marie-Josée Brouillette, et al.
Molecular Diagnosis & Therapy|January 31, 2023
A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial FibrillationGisèle Nakhlé, Jean-Claude Tardif, Denis Roy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 20, 2006
Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trialStéphane Rinfret, David J Cohen, Amir A Tahami Monfared, et al.
The Canadian Journal of Cardiology|June 12, 2013
Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategiesFrédéric Poulin, Paul Khairy, Denis Roy, et al.
Pharmacoepidemiology and Drug Safety|March 20, 2003
Bringing epidemiology into drug utilisation researchJacques LeLorier, Robert H Vander Stichele, Jerry Avorn, et al.
Clinical Kidney Journal|June 16, 2017
The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patientsFanny Lepeytre, Héloise Cardinal, Lorraine Fradette, et al.
Current Medical Research and Opinion|March 5, 2008
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian settingJacques LeLorier, Mei Sheng Duh, Pierre Emmanuel Paradis, et al.
JAAD International|August 23, 2022
Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasisRaymond Milan, Jacques LeLorier, Eric A Latimer, et al.
The American Journal of Cardiology|January 25, 2011
Analysis of willingness to pay for implantable cardioverter-defibrillator therapyDominika Nowakowska, Jason R Guertin, Aihua Liu, et al.
The Canadian Journal of Cardiology|July 13, 2011
Atrial fibrillation: a real-life observational study in the Québec populationJason R Guertin, Marc Dorais, Paul Khairy, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
JAAD International|August 19, 2021
Sex differences in factors associated with switch between systemic agents among individuals with psoriasis: A retrospective cohort study in Quebec, CanadaRaymond Milan, Jacques LeLorier, Marie-Josée Brouillette, et al.
Molecular Diagnosis & Therapy|January 31, 2023
A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial FibrillationGisèle Nakhlé, Jean-Claude Tardif, Denis Roy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 20, 2006
Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trialStéphane Rinfret, David J Cohen, Amir A Tahami Monfared, et al.
The Canadian Journal of Cardiology|June 12, 2013
Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategiesFrédéric Poulin, Paul Khairy, Denis Roy, et al.
Pharmacoepidemiology and Drug Safety|March 20, 2003
Bringing epidemiology into drug utilisation researchJacques LeLorier, Robert H Vander Stichele, Jerry Avorn, et al.
Clinical Kidney Journal|June 16, 2017
The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patientsFanny Lepeytre, Héloise Cardinal, Lorraine Fradette, et al.
Current Medical Research and Opinion|March 5, 2008
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian settingJacques LeLorier, Mei Sheng Duh, Pierre Emmanuel Paradis, et al.
JAAD International|August 23, 2022
Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasisRaymond Milan, Jacques LeLorier, Eric A Latimer, et al.
The American Journal of Cardiology|January 25, 2011
Analysis of willingness to pay for implantable cardioverter-defibrillator therapyDominika Nowakowska, Jason R Guertin, Aihua Liu, et al.
The Canadian Journal of Cardiology|July 13, 2011
Atrial fibrillation: a real-life observational study in the Québec populationJason R Guertin, Marc Dorais, Paul Khairy, et al.
Pageof 10